Want to join the conversation?
$TRV's shareholders' equity rose by 5% to $24.714Bil at June 30, 2016 from year-end 2015, primarily due to an increase in after-tax net unrealized investment gains. Book value per share increased by 7% to $85.73 and adjusted book value per share rose by 3% to $77.61 from year-end 2015.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.